Leonard Zehr, Author at BioTuesdays

Feature

TransMedics redefining what’s possible in organ transplantation

TransMedics Group (NASDAQ:TMDX) is transforming the standard of care in solid organ transplants in order to increase the number of organ transplants and improve clinical outcomes.

May 4, 2021

Feature

Stuart Long outlines InfoBionic remote cardiac arrhythmia monitoring benefits

As CEO of InfoBionic, a closely held digital health company with an initial focus on cardiac arrhythmia detection and monitoring, Stuart Long knows his way around achieving commercial growth in the medical device market...

April 27, 2021

Feature

ViaCyte developing stem cell-derived islet replacement for diabetes

Closely held ViaCyte, a company with two decades of experience, is utilizing pluripotent stem cell technology and novel delivery approaches to address multiple disease areas, with an initial focus and lead products...

April 20, 2021

Feature

Cyclacel translating cancer biology into potential medicines

Cyclacel (NASDAQ:CYCC) is developing several innovative therapies that target various phases of cell cycle control for the treatment of solid tumor and blood-borne cancers, such as leukemia.

April 13, 2021

Feature

Varsha Rao talks up Nurx convenient and affordable care for sensitive health needs

As CEO of closely-held Nurx, the leading female-focused telehealth platform offering patients transparent pricing and judgment-free care, Varsha Rao brings decades of experience balancing mission-driven companies with a...

March 30, 2021

Feature

KA Imaging Reveal device a game changer in reinventing X-ray with dual energy

X-ray manufacturer, KA Imaging, is reinventing dual energy X-rays with its Reveal 35C device, which can produce three images from a single exposure, overcoming clinical and technical issues that exist with traditional X...

March 23, 2021

Feature

Petros Pharma looking to pursue OTC status for its Stendra erectile dysfunction therapy

Petros Pharmaceuticals (NASDAQ:PTPI) has set up a steering committee with the aim of applying to the FDA to make its prescription erectile dysfunction (ED) therapy, Stendra, available as an over-the-counter product in a...

March 16, 2021

Feature

Kezar Life Sciences harnessing master regulators of cellular functions to tackle disease

Kezar Life Sciences (NASDAQ:KZR) is advancing two drug development programs that have the potential to address a number of indications by harnessing different “master regulators” of cellular function: protein...

March 9, 2021

Feature

111’s next-gen S2B2C model is transforming China’s legacy healthcare system

Shanghai-based 111, Inc. (NASDAQ:YI) is helping pioneer the S2B2C model in China as it builds an innovative healthcare platform in the country.

March 2, 2021

Feature

Keith Sullivan discusses turnaround plan for Neuronetics

As the recently installed president and CEO of Neuronetics (NASDAQ:STIM), a commercial-stage medical device company focused on designing, developing and marketing products that improve the quality of life for patients...

February 23, 2021

Author - Leonard Zehr

TransMedics redefining what’s possible in organ transplantation

Stuart Long outlines InfoBionic remote cardiac arrhythmia monitoring benefits

ViaCyte developing stem cell-derived islet replacement for diabetes

Cyclacel translating cancer biology into potential medicines

Varsha Rao talks up Nurx convenient and affordable care for sensitive health needs

KA Imaging Reveal device a game changer in reinventing X-ray with dual energy

Petros Pharma looking to pursue OTC status for its Stendra erectile dysfunction therapy

Kezar Life Sciences harnessing master regulators of cellular functions to tackle disease

111’s next-gen S2B2C model is transforming China’s legacy healthcare system

Keith Sullivan discusses turnaround plan for Neuronetics

Subscribe